BibTex RIS Cite

HEPATITIS A VACCINES

Year 2002, Volume: 15 Issue: 1, 63 - 65, 03.12.2016

Ozan Kocakaya Erol Avşar

Abstract

As countries prosper, anti-HAV seroprevalance decreases; that is why infection is more commonly encountered in advanced age cases in developed countries. The presence of the risk of developing fulminant hepatitis and the increase in touristic travels to endemic areas, emphasizes the importance of active immunization. Studies for preparing a vaccine started in the late 70's and the first vaccine was introduced in 1992.

References

  • Lewis JA. Hepatitis A vaccines. In: Specter S, ed. Viral Hepatitis. Diagnosis. Therapy and Prevention. Totowa, Hew Jersey, Humana Press, 1999;31 7-375.
  • Clemens R, Safarya A, Hepburn A, et at. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995:171 (Suppl I;)44-49.
  • Tholen S, Van Damme P, Leentvaar A, et at. The first combined vaccine against hepatitis A and B: an overwiew. Vaccine 1999; 1 7:1657- 1662.
  • Innis BL, Snitbhan R, Runasal P, et ai. Protection against hepatitis A by an inactivated vaccine. JAMA 1994;271:1328- 1334.
  • Van Damme P, Tholen S, Cramm K, et al. Inactivated hepatitis A vaccines: reactogenicity, immunogenicity and long term antibody persistence. J Med Virol I994;44: 446-451.
  • Lee SD, Chan CY, Yu Ml, et al. Safety and immunogenicity of inactivated hepatitis /I vaccine in patients with chronic liver disease. J Med Virol 1997;52:215-218.

Year 2002, Volume: 15 Issue: 1, 63 - 65, 03.12.2016

Ozan Kocakaya Erol Avşar

Abstract

References

  • Lewis JA. Hepatitis A vaccines. In: Specter S, ed. Viral Hepatitis. Diagnosis. Therapy and Prevention. Totowa, Hew Jersey, Humana Press, 1999;31 7-375.
  • Clemens R, Safarya A, Hepburn A, et at. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995:171 (Suppl I;)44-49.
  • Tholen S, Van Damme P, Leentvaar A, et at. The first combined vaccine against hepatitis A and B: an overwiew. Vaccine 1999; 1 7:1657- 1662.
  • Innis BL, Snitbhan R, Runasal P, et ai. Protection against hepatitis A by an inactivated vaccine. JAMA 1994;271:1328- 1334.
  • Van Damme P, Tholen S, Cramm K, et al. Inactivated hepatitis A vaccines: reactogenicity, immunogenicity and long term antibody persistence. J Med Virol I994;44: 446-451.
  • Lee SD, Chan CY, Yu Ml, et al. Safety and immunogenicity of inactivated hepatitis /I vaccine in patients with chronic liver disease. J Med Virol 1997;52:215-218.
There are 6 citations in total.

Details

Journal Section Prevention & Control
Authors

Ozan Kocakaya This is me

Erol Avşar This is me

Publication Date December 3, 2016
Published in Issue Year 2002 Volume: 15 Issue: 1

Cite

APA Kocakaya, O., & Avşar, E. (2016). HEPATITIS A VACCINES. Marmara Medical Journal, 15(1), 63-65.
AMA Kocakaya O, Avşar E. HEPATITIS A VACCINES. Marmara Med J. March 2016;15(1):63-65.
Chicago Kocakaya, Ozan, and Erol Avşar. “HEPATITIS A VACCINES”. Marmara Medical Journal 15, no. 1 (March 2016): 63-65.
EndNote Kocakaya O, Avşar E (March 1, 2016) HEPATITIS A VACCINES. Marmara Medical Journal 15 1 63–65.
IEEE O. Kocakaya and E. Avşar, “HEPATITIS A VACCINES”, Marmara Med J, vol. 15, no. 1, pp. 63–65, 2016.
ISNAD Kocakaya, Ozan - Avşar, Erol. “HEPATITIS A VACCINES”. Marmara Medical Journal 15/1 (March 2016), 63-65.
JAMA Kocakaya O, Avşar E. HEPATITIS A VACCINES. Marmara Med J. 2016;15:63–65.
MLA Kocakaya, Ozan and Erol Avşar. “HEPATITIS A VACCINES”. Marmara Medical Journal, vol. 15, no. 1, 2016, pp. 63-65.
Vancouver Kocakaya O, Avşar E. HEPATITIS A VACCINES. Marmara Med J. 2016;15(1):63-5.